Growth factor involvement in progression of prostate cancer

Clinical Chemistry

Volumn 44, Issue 4, 1998, Pages 705-723

  Russell, Pamela J ^a,b   Bennett, Suzanne ^a,b   Stricker, Phillip ^c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; ANDROGEN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; COLECALCIFEROL; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; RETINOIC ACID; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; CANCER CELL CULTURE; CANCER GROWTH; GENE MUTATION; HUMAN; MALE; NONHUMAN; PROSTATE CANCER; RECEPTOR UPREGULATION; REVIEW; TRANSGENIC MOUSE; XENOGRAFT;

ANIMALS; DISEASE PROGRESSION; EPITHELIAL CELLS; GROWTH SUBSTANCES; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; STROMAL CELLS; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0031926061     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (230)

1. Seidman H, Mushinski MH, Gelb SK, Silverberg E. Probabilities of eventually developing or dying of cancer: United States. Cancer J Clin 1985;35:36-56.
2. Coates M, Armstrong B. Cancer in NSW. Incidence and Mortality 1994:58-9.
3. Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. Cancer J Clin 1990;44:7-26.
4. McNeal JE, Bostwick DG, Kindrachuk RA, Redwine EA, Freiha FS, Stamey TA. Patterns of progression in prostate cancer. Lancet 1986;i:60-3.
5. Rosen MA. Impact of PSA screening on the natural history of prostate cancer. Urology 1995;46:757-68.
6. Aikara M, Wheeler TM, Ohori M, Scardino PT. Heterogeneity of prostate cancer in radical prostatectomy specimens. Urology 1994;43:60-7.
7. van den Ouden D, Tribukait B, Blom JHM, Fossa SD, Kurth KH, ten Kate FJ, et al. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: impact on time to progression. The European Organization for Research and Treatment of Cancer Genitourinary Group. J Urol 1993;150: 400-6.
8. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localised prostate cancer. N Engl J Med 1994;330:242-8.
9. Coffey DS. The molecular biology of the prostate. In: Lepor H, Lawson RK, eds. Prostate diseases. Philadelphia: Saunders, 1993:28-56.
10. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28:98-106.
11. Coffey DS. The molecular biology, endocrinology and physiology of the prostate and seminal vesicles. In: Walsy PC, Refik AB, Stamey TA, Vaughan ED, eds. Campbell's urology, 6th ed. Philadelphia: Saunders, 1992:221-51.
12. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-62.
13. Gleave ME, Hsieh J-T. Animal models in prostate cancer. In: Raghavan D, Scher HI, Leibel SA, Lange PH, eds. Principles and practice of genitourinary oncology. Philadelphia: Lippincott-Raven Publishers, 1997:367-78.
14. Catalona WJ. Management of cancer of the prostate. N Engl J Med 1994;331:996-1004.
15. Lubahn DB, Joseph DR, Sar M, Tan J, Higgs HN, Larson RE, et al. The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol Endocrinol 1988;2:1265-75.
16. Lee C. Role of androgen in prostate growth and regression: stromal-epithelial interaction. Prostate 1996;6(Suppl):52-6.
17. Chung LWK, Gleave ME, Hsieh J, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate tumor growth and hormonal responsiveness. Cancer Surv 1991;11: 91-119.
18. Sadi MV, Walsh PC, Barrack ER. Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapy. Cancer 1991;67:3057-64.
19. Chodak GW, Kranc DM, Puy LA, Takeda H, Johnson K, Chang C. Nuclear localization of androgen receptor in heterogeneous samples of normal prostate, hyperplastic and neoplastic human prostate. J Urol 1992;147:798-803.
20. Bentel JM, Tilley WD. Androgen receptors in prostate cancer. J Endocrinol 1996;151:1-11.
21. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, et al. Mutations of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332: 1393-8.
22. Gaddipati JP, Mcleod DG, Heidenbery HB, Seterhen IA, Finger MJ, Moul JW. Frequent detection of codon 877 mutations in the androgen receptor gene in advanced prostate cancer. Cancer Res 1994;54:2861-4.
23. Veldscholte J, Voorhorst-Ogink MM, Bolt-de Vries J, van Rooji HCJ, Trapman J, Mulder E. Unusual specificity of the androgen receptor in the human prostate tumour cell line LNCaP: high affinity for progestogenic and estrogenic steroids. Biochim Biophys Acta 1990;1052:187-94.
24. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fishbeck KH, et al. Microsatellite mutation (CAG 24-18) in the androgen receptor in human prostate cancer. Biochem Biophys Res Commun 1994;198:74-80.
25. Rundlett SE, Wu XP, Miesfeld RL. Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 1990;4:7211-5.
26. Simental JA, Sar M, Lane MV, French FS, Wilson EM. Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 1991;226:510-8.
27. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, et al. Androgen receptor activation in prostatic tumour cell lines by a insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994;54:5474-8.
28. Schuurmans AL, Bolt J, Mulder E. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol Cell Endocrinol 1988;60:101-4.
29. Story MT, Hopp KA, Meier D. Regulation of basic fibroblast growth factor expression by transforming growth factor beta in cultured human prostate stroma cells. Prostate 1996;28:219-26.
30. Timme TL, Truong LD, Slavin KM, Kadmon D, Park SH, Thompson TC. Mesenchymal-epithelial interactions and transforming growth factor-beta 1 expression during normal and abnormal prostatic growth. Microsc Res Tech 1995;30:333-41.
31. Landstrom M, Eklov S, Colosetti P, Nilsson S, Damber JE, Bergh A, Funa K. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Int J Cancer 1996;67: 573-9.
32. Kyprianou N, English HF, Davidson NE, Isaacs JT. Programmed cell death during regression of the PC-82 human prostate cell line following androgen ablation. Cancer Res 1990;90:3748-53.
33. Roberts AB, Sporn MB. Transforming growth factors. Cancer Surv 1985;4:683-705.
34. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC. Association of transforming growth factor beta 1 with prostate cancer. Hum Pathol 1993;24:4-9.
35. Kahehi Y, Oka H, Mitsumori K, Itoh N, Ogawa O, Yoshida O. Elevation of serum transforming growth factor-β1 level in patients with metastatic prostate cancer. Urol Oncol 1996;2: 131-5.
36. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, et al. Elevated transforming growth factor beta 1 and beta 3 mRNA levels are associated with ras+myc-induced carcinomas in reconstituted mouse prostate: evidence for a paracrine role during progression. Mol Endocrinol 1991;5:503-13.
37. Sehgal I, Baley PA, Thompson TC. Transforming growth factor beta 1 stimulates contrasting responses in metastatic versus primary mouse prostate cancer-derived cell lines in vitro. Cancer Res 1996;56:3359-65.
38. Steiner MS, Barrack ER. Transforming growth factor-beta 1 overproduction in prostate cancer: effects on growth in vivo and in vitro. Mol Endocrinol 1992;6:15-25.
39. Kim IY, Ahn HJ, Zelner DJ, Shaw JW, Sensibar JA, Kim JH, et al. Genetic changes in transforming growth factor beta (TGF-beta) receptor type 1 gene correlates with insensitivity to TGF-beta 1 in human prostate cancer. Cancer Res 1996;56:44-8.
40. Kim IY, Ahn H-J, Zelner DJ, Shaw JW, Lang S, Kato M, et al. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-61.
41. Steiner MS, Anthony CT, Metts J, Moses HL. Prostate cancer cells lose their sensitivity to TGFβ1 growth inhibition with tumor progression. Urol Oncol 1995;1:252-62.
42. Roberts AB, Heine UI, Flanders KC, Sporn MB. Transforming growth factor-β. Major role in regulation of extracellular matrix. Part IV. Developmental biology of collagen. Ann N Y Acad Sci 1990;580:225-32.
43. McCartney-Francis N, Mizel D, Wong H, Wahl L, Wahl S. Transforming growth factor beta (TGF-β) as an immunoregulatory molecule. FASEB J 1988;2:A875.
44. Lind M, Deleuran B, Thestrup-Pedersen K, Soballe K, Eriksen EF, Bunger C. Chemotaxis of human osteoblasts. Effects of osteotropic growth factors. Acta Pathol Microbiol Immunol Scand 1995;103:140-6.
45. Sherwood ER, Fong C-J, Lee C, Kozlowsski JM. Basic fibroblast growth factor: a potential mediator of stromal growth in the human prostate. Endocrinology 1992;130:2955-63.
46. Story MT, Livingston B, Baeton L, Swartz SJ, Jacobs SC, Begun FP, et al. Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 1989;15:355-65.
47. Nakamoto T, Chang C, Li A, Chodak GW. Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 1992;52: 571-7.
48. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL. Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993;13:4513-22.
49. Muller WJ, Lee FS, Dickson C, Peters G, Pattengale P, Leder P. The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 1990;9:907-13.
50. Folkman J. What is the evidence that tumours are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
51. Mansson PE, Adams P, Kan M, McKeehan WL. Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostatic tumors. Cancer Res 1989;49:2485-94.
52. McKeehan WL. Growth factor receptors and prostate cell growth. Cancer Surv 1991;11:165-75.
53. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL. Heparin-binding keratinocyte growth factor is a candidate stromal-to epithelial-cell andromedin. Mol Endocrinol 1992;6: 2123-8.
54. Mansukhani A, Dell'Era P, Moscatelli D, Kornbluth S, Hanafusa H, Basilico C. Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. Proc Natl Acad Sci U S A 1992;89:3305-9.
55. McGarvey TW, Sterans ME. Keratinocyte growth factor and receptor mRNA expression in benign and malignant human prostate. Exp Mol Pathol 1995;63:52-62.
56. Leung HY, Mehta P, Gray LB, Collins AT, Robson CN, Neal DE. Keratinocyte growth factor expression in hormone insensitive prostate cancer. Oncogene 1997;15:1115-20.
57. Schmitt JF, Hearn MT, Risbridger GP. Expression of fibroblast growth factor-8 in adult rat tissues and human prostate carcinoma cells. J Steroid Biochem Mol Biol 1996;57:173-8.
58. Cohen P, Peehl DM, Lamson G, Rosenfeld R. Insulin-like growth factors (IGF's) IGF receptors, and IGF binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991;73:401-7.
59. Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 1996;81:612-7.
60. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines, LNCaP, DU145, and PC-3 cell. Int J Urol 1996;3:39-46.
61. Kanety H, Madjar Y, Dagen Y, Levi J, Papa MZ, Pariente C, et al. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 1993;77:229-33.
62. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS. Altered growth and insulin-like growth factor-binding protein-3 production in PC-3 prostatic carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 1995;136:1040-8.
63. Chevalley T, Strong DD, Mohan S, Baylink DJ, Linkhart TA. Evidence for a role of insulin-like growth factor binding proteins in glucocorticoid inhibition of normal human osteoblast-like cell proliferation. Eur J Endocrinol 1996;134:591-601.
64. Gregory J, Willshire IR, Kavanagh JP, Blacklock NJ, Chowdury S, Richards RC. Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. Clin Sci 1986;70:359-63.
65. St. Arnaud R, Poyet P, Walker P, Labrie F. Androgens modulate epidermal growth factor expression in the rat ventral prostate. Mol Cell Endocrinol 1988;56:21-7.
66. Hiramatsu M, Kashinmata M, Minami N, Sato A, Murayama M. Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 1988;17:311-7.
67. Nishi N, Oya H, Matsumoto K, Nakamura T, Miyanaka H, Wada F. Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates. Prostate 1996;28:139-52.
68. Fowler JE, Tau LK, Ghosh L. Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 1988;139:857-61.
69. Yang Y, Chisholm GD, Habib FK. Epidermal growth factor and transforming growth factor alpha concentrations in BPH and cancer of the prostate: their relationship with tissue androgen levels. Br J Cancer 1993;67:152-5.
70. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K. An immunochemical analysis of TGF-alpha expression in benign and malignant prostate. Prostate 1993;23:9-23.
71. Glynne-Jones E, Goddard L, Harper ME. Comparative analysis of mRNA and protein expression for epidermal growth factor receptor and ligands relative to the proliferative index in human prostate tissue. Hum Pathol 1996;27:688-94.
72. Cohen DW, Simak R, Fair WR, Melded J, Scher HI, Cordon-Cardo C. Expression of transforming growth factor-alpha and the epidermal growth factor receptor in human prostatic tissue. J Urol 1994;152:2120-4.
73. Jarrad DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB. Effects of epidermal growth factor on prostate cancer line PC-3 growth and invasion. Prostate 1994;24:46-53.
74. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi M, et al. Insulin-like growth factor (IGF) system components in human prostatic cancer cell lines: LNCaP, DU145and PC-3 cells. Int J Urol 1996;3:39-46.
75. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-11.
76. Graham CW, Lynch JH, Djakiew D. Distribution of nerve growth factor-like protein and nerve growth factor receptor in human benign prostatic hyperplasia and prostatic adenocarcinoma. J Urol 1992;147:1444-7.
77. Pflug BR, Onoda M, Lynch JH, Djakiew D. Reduced expression of the low affinity nerve growth factor receptor in benign and malignant human prostate tissue and loss of expression in four human metastatic prostate tumor cell lines. Cancer Res 1992; 52:5403-6.
78. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW. Interleukin-6, a candidate mediator of human prostate cancer morbidity. Urology 1995;45:542-9.
79. Siegsmund MJ, Yamazaki H, Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. J Urol 1994;151:1396-9.
80. Coffey DS, Isaacs JT. Requirement for an idealized animal model of prostatic cancer. Prog Clin Biol Res 1980;37:379-88.
81. Dunning WR. Prostate cancer in the rat. Natl Cancer Inst Monogr 1963;12:351-69.
82. Isaacs JT. Development and characteristics of the available animal models for the study of prostate cancer. In: Coffey DS, Bruchovsky N, Gardner WH, Resnick MI, Karr JP, eds. Current approaches to the study of prostate cancer. New York: Alan R. Liss, 1987:513-75.
83. Voigt W, Feldman M, Dunning WF. 5α-Dihydrotestosterone-binding proteins and androgen sensitivity in prostatic cancer of Copenhagen rats. Cancer Res 1975;35:1840-6.
84. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-81.
85. Noble RL, Hoover L. The classification of transplantable tumors in Nb rats controlled by estrogen from dormancy to autonomy. Cancer Res 1975;35:2935-41.
86. Noble RL. The development of prostatic adenocarcinoma in the Nb rat following prolonged sex hormone administration. Cancer Res 1977;37:1929-33.
87. Drago JR, Goldman LB, Gerswin ME. Chemotherapeutic and hormonal considerations of the Nb rat prostatic adenocarcinoma model. Prog Clin Biol Res 1980;37:325-63.
88. Drago JR, Curley RM, Sipio J. Nb rat prostatic adenocarcinoma model: metastasis. Anticancer Res 1985;5:193-6.
89. Chung LWK, Chang SM, Bell C, Zhau HE, Ro JY, von Eschenbach AC. Co-inoculation of tumorigenic rat prostate mesenchymal cells with nontumorigenic epithelial cells results in the development of carcinosarcoma in syngeneic and athymic animals. Int J Cancer 1989;43:1179-87.
90. Pollard M. Spontaneous prostate adenocarcinomas in aged germfree Wistar rats. J Natl Cancer Inst 1973;51:1235-41.
91. Pollard M, Luckert P. Prostate cancer in a Sprague-Dawley rat. Prostate 1985;6:389-93.
92. Cohen MB, Heidger PM, Lubaroff DM. Gross and microscopic pathology of induced prostatic complex tumors arising in Lobund-Wistar rats. Cancer Res 1994;54:626-8.
93. Shain SA, McCullough B, Segaloff A. Spontaneous adenocarcinomas of the ventral prostate of aged AXC rats. J Natl Cancer Inst 1975;55:177-80.
94. Shain SA, Boesel RW, Kalter SS, Heberling RL. AXC rat prostatic adenocarcinoma: initial characterization of testosterone regulation of hormone receptors of cultured cancer cells and derived tumors. J Natl Cancer Inst 1981;66:565.
95. Minesita T, Yamaguchi K. An androgen-dependent mouse mammary tumor. Cancer Res 1964;25:1168-75.
96. Bruchovsky N. The metabolism of testosterone and dihydrotestosterone and tumor growth in vivo. Biochem J 1972;127:561-75.
97. Thompson TC, Southgate J, Kitchener, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989;56:917-30.
98. Claas FHJ, van Steenbrugge GJ. Expression of HLA-like structures on a permanent human tumor line PC-93. Tissue Antigens 1983;21:227-32.
99. Kaighn M, Shakar Narayan K, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979;17:16-23.
100. Mickey D, Stone K, Wunderli H, Mickey G, Vollmer R, Paulson D. Hetero-transplantation of a human prostatic adenocarcinoma cell line in nude mice. Cancer Res 1977;37:4049-58.
101. Horoszewicz J, Leong S, Chu T, Wajsman Z, Friedman M, Papsidero L, et al. The LNCaP cell line: a new model for studies on human prostatic carcinoma. Prog Clin Biol Res 1980;37: 115-32.
102. Wu H-C, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgen-independent LNCaP prostate cancer sublines: role of bone stromal cells. Int J Cancer 1994;57:406-12.
103. Thalmann GN, Anezinis PE, Chang SH, Ahau HE, Kim EE, Hopwood VL, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
104. Umekita Y, Hiipakka RA, Kokontis JM, Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 1996;93: 11802-7.
105. Nagablushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, et al. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56: 3042-6.
106. Hoehn W, Schroeder F, Riemann J, Joebsis A, Hermanek P. Human prostatic adenocarcinoma: some characteristics of a serially transplantable line in nude mice (PC-82). Prostate 1980; 1:95-104.
107. van Weerden WM, van Kreuningen A, Elissen NM, Vermeij M, de Jong FH, van Steenbrugge GJ, Schroder FH. Castration induced changes in morphology, androgen levels and proliferation activity of human prostate tissue grown in athymic nude mice. Prostate 1993;23:149-63.
108. Ito Y, Nakazato Y. A new serially transplantable human prostatic cancer (Honda) in nude mice. J Urol 1984;132:384-7.
109. Bladou F, Vessella RL, Buhler KR, Ellis WJ, True LD, Lange PH. Cell proliferation and apoptosis during prostatic tumor xenograft involution and regrowth after castration. Int J Cancer 1996;67: 785-90.
110. Pittman S, Russell PJ, Jelbart ME, Wass J, Raghavan D. Flow cytometric and karyotypic analysis of a primary small cell carcinoma of the prostate: a xenografted cell line. Cancer Genet Cytogenet 1987;26:165-9.
111. Jelbart M, Russell PJ, Fullerton M, Russell P, Funder J, Raghavan D. Ectopic hormone production by a prostatic small cell carcinoma xenograft line. Mol Cell Endocrinol 1988;55:167-72.
112. Cunha GR, Fujii H, Neubauer BL, Shannon JM, Sawyer L, Reese BA. Epithelial-mesenchymal interactions in prostate development. I, Morphological observations of prostatic induction by urogenital sinus mesenchyme in epithelium of adult rodent urinary bladder. J Cell Biol 1983;96:1662-70.
113. Rennie PS, Bruchovsky N, Coldman AJ. Loss of androgen-dependence is associated with an increase in tumorigenic stem cells and resistance to cell-death genes. J Steroid Biochem Mol Biol 1990;37:843-7.
114. Iizumi T, Yazaki T, Kanoh S, Kondo I, Koiso K. Establishment of a new prostatic carcinoma cell (TSU-PR1). J Urol 1987;137: 1304-6.
115. Pettaway CA, Pathak S, Greene G, Ramirez E, Wilson MR, Killion JJ, Fidler IJ. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin Cancer Res 1996;2:1627-36.
116. Gleave ME, Hsieh JT, Gao CA, von Eschenbach AC, Chung LWK. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991; 51:3753-61.
117. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LWK. Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional stromal-epithelial interactions in prostate carcinoma growth and metastasis. J Urol 1992;147: 1151-9.
118. Chung LWK, Gleave ME, Hsieh JT, Hong SJ, Zhau HE. Reciprocal mesenchymal-epithelial interaction affecting prostate cancer growth and hormonal responsiveness. Cancer Surv 1991;11: 91-121.
119. Hsieh JT, Wu H-C, Gleave ME, von Eschenbach AC, Chung LW. Autocrine regulation of PSA gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 1993;53:2852-7.
120. Ruizeveld de Winter JA, van Weerden WM. Faber PW, van Steenbrugge GJ, Trapman J, Brinkmann AO, van der Kwast TH. Regulation of androgen receptor expression in the human heterotransplantable prostate carcinoma PC-82. Endocrinology 1992;131:3045-50.
121. Sandgren EP, Leutteke NC, Palmiter RD, Brinster RL, Lee DD. Overexpression of TGFalpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 1990;61:1121-35.
122. Greenberg NM, de Mayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
123. Shibata MA, Ward JM, Devor DE, Liu ML, Green JE. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3 (1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. Cancer Res 1996;56:4894-903.
124. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, De Mayo FJ, Finegold MJ, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-102.
125. Roberts AB, Sporn MB. The transforming growth factor betas. In: Sporn MB, Roberts AB, eds. Peptide growth factors and their receptors: handbook of experimental pharmacology. Volume 95-1. Heidelberg: Springer-Verlag, 1990:419-72.
126. Merz VW, Arnold AM, Studer UE. Differential expression of transforming growth factor-beta 1 and beta 3 as well as c-fos mRNA in normal human prostate, benign prostatic hyperplasia and prostatic cancer. World J Urol 1994;12:96-8.
127. Graycar JL, Miller DA, Arrick BA, Lyons RM, Moses HL, Derynck R. Human transforming growth factor-beta 3; recombinant expression, purification and biological activities in comparison with transforming growth factors-beta 1 and -beta 2. Mol Endocrinol 1989;3:1977-86.
128. Miller DA, Pelton RW, Derynck R, Moses HL. Transforming growth factor beta. Ann N Y Acad Sci 1990;593:208-17.
129. Chen R, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-β activities. Science 1993;260:1335-8.
130. Atfi A, Drobetsky E, Boissonneault M, Chapdelaine A, Chevalier S. Transforming growth factor beta down-regulates src family protein tyrosine kinase signalling pathways. J Biol Chem 1994; 269:30688-93.
131. Sietzer U, Batge B, Acil Y, Muller PK. Transforming growth factor beta 1 influences lysyl hydroxylation of collagen I and reduces steady-state levels of lysyl hydroxylase mRNA in human osteoblast-like cells. Eur J Clin Invest 1995;25:959-66.
132. Miyazono K. TGF-beta receptors and signal transduction. Int J Hematol 1997;65:97-104.
133. Massagué J. Transforming growth factor-alpha. A model for membrane-anchored growth factors. J Biol Chem 1990;265: 21393-6.
134. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990;265:7709-12.
135. Ulrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 1984;309:418-24.
136. Florkiewicz RZ, Baird A, Gonzalez AM. Multiple forms of bFGF: differential nuclear and cell surface localization. Growth Factors 1991;4:265-75.
137. Renko M, Quarto N, Morimoto T, Rifkin DB. Nuclear and cytoplasmic localization of different basic fibroblast growth factor species. J Cell Physiol 1990;144:108-14.
138. D'Amore PA. Modes of FGF release in vivo and in vitro. Cancer Metastasis Rev 1990;9:227-38.
139. Gimenez-Gallego G, Rodkey J, Bennett C, Rios-Candelore M, Disalvo J, Thomas K. Brain-derived acidic fibroblast growth factor: complete amino acid sequence and homologies. Science 1985;230:1385-8.
140. Yan GC, Nikolaropolous S, Wang F, McKeehan WL. Sequence of rat keratinocyte growth factor (heparin-binding growth factor 7). In Vitro Cell Dev Biol 1991;27A:437-8.
141. Finch PW, Rubin JS, Miki A. Human KGF is a FGF-related with properties of a paracrine effector of epithelial cells. Science 1989;245:752-5.
142. Daughady WH, Rotwein P. Insulin-like growth factors 1 and 11, peptide, messenger ribonucleic acid and gene structures, serum and tissue concentrations. Endocr Rev 1989;10:68-91.
143. Czech MP. Signal transmission by the insulin-like growth factors. Cell 1989;59:235-8.
144. Rosenfeld RG, Lamson GL, Hung P. Insulin-like growth factor binding proteins. Recent Prog Horm Res 1990;46:99-163.
145. Wilding G. Response of prostate cancer cells to peptide growth factors: transforming growth factor-β. Cancer Surv 1991;11: 147-62.
146. Derynck R, Lindquist PB, Lee A, Wen D, Tamm J, Graycar JL, et al. A new type of transforming growth factor-beta, TGF-beta 3. EMBO J 1988;7:3737-43.
147. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty AJ, Angel P, Heath JK. Transforming growth factor beta modulates the expression of collagenase and rnetalloproteinase inhibitor. EMBO J 1989;6:1899-1904.
148. Battegay EJ, Raines EW, Seifert RA, Bowen-Pope DF, Ross R. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell 1990;53: 515-29.
149. Laiho M, DeCaprio JA, Ludlow JW, Livingstone DM, Massagué J. Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 1990;62:175-85.
150. Miyazono K, Olofsson A, Colosetti P, Heldin CH. The role of the latent TGF-beta-1 binding protein in the assembly and secretion of TGF-beta 1. EMBO J 1991;10:1091-101.
151. Eklov S, Funa K, Nordgen H, Olofsson A, Kanzaki T, Miyazono K, Nilsson S. Lack of the latent transforming growth factor beta binding protein in malignant but not benign prostatic tissue. Cancer Res 1993;53:3193-7.
152. Wilding G, Zugmeier G, Knabbe C, Flanders K, Gelmann E. Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 1989;62:79-87.
153. Ikeda T, Lioubin MN, Marquardt H. Human transforming growth factor type β 2: production by a prostatic adenocarcinoma cell line, purification and initial characterization. Biochemistry 1987; 26:2406-10.
154. Bascom CC, Wolfshohl JR, Coffey RJ Jr, Madisen L, Webb NR, Purchio AR, et al. Complex regulation of transforming growth factor beta 1 and beta 2. Mol Cell Biol 1989;9:5508-15.
155. Kostenuik PJ, Singh G, Orr FW. Transforming growth factor beta upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen. Clin Exp Metastasis 1997; 15:41-52.
156. McKeehan WL, Adams PS, Rosser MP. Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free primary cell culture. Cancer Res 1984;44:1998-2010.
157. Peehl DM, Wong S, Bazinet M, Stamey TA. In vitro studies of human prostatic epithelial cells. Attempts to identify distinguishing features of malignant cells. Growth Factors 1989;1:237-50.
158. Schuurmans ALG, Bolt J, Mulder E. Androgen receptor-mediated growth and epidermal growth factor receptor induction in human prostate cell lines LNCaP. Urol Int 1989;44:71-6.
159. Chung LW, Li W, Gleave ME, Sikes RA, Zhau HE, Bandyk MG, et al. Human prostate cancer model: roles of growth factors and extracellular matrices. J Cell Biochem Suppl 1992;16:99-105.
160. Wu H-C, Hsieh JT, Gleave ME, Chung LWK. Characterization of growth and differentiation-associated gene activities during the progression of prostate cancer from androgen-responsive to androgen-refractory status [Abstract]. Cancer Res 1992;33: 1651.
161. Connolly JM, Rose DP. Production of epidermal growth factor and transforming growth factor-alpha by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 1990;16:209-18.
162. Connolly JM, Rose DP. Secretion of epidermal growth factor and related polypeptides by the Du145 human prostate cell line. Prostate 1989;15:177-86.
163. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992;65:177-82.
164. Ching KZ, Ramsay E, Pettigrew N, D'Cunha R, Jason M, Dodd JG. Expression of mRNA for epidermal growth factor, transforming growth factor-alpha and their receptors in human prostate tissue and cell lines. Mol Cell Biochem 1993;126:151-8.
165. Carruba G, Leake RE, Rinaldi F, Chalmers D, Comito L, Sorci C, et al. Steroid-growth factor interaction in human prostate cancer. 1, Short-term effects of transforming growth factors on growth of human prostate cancer cells. Steroids 1994;59:412-20.
166. Roberston CN, Roberson KM, Herzberg AJ, Kerns BJ, Dodge RK, Paulson DF. Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissue. Surg Oncol 1994;3:237-42.
167. MacDonald A, Habib FK. Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 1992;65:177-82.
168. Fox SB, Persad RA, Coleman N, Day CA, Silcocks PB, Collins CC. Prognostic value of c-erb-2 and epidermal growth factor receptor in stage A1 (T1a) prostatic carcinoma. Br J Urol 1994;74:214-20.
169. Turkeri LN, Sakr WA, Wydes SM, Grignon DJ, Pontes JE, Macoska JA. Comparative analysis of epidermal growth factor receptor expression and protein product in benign, pre-malignant, and malignant prostatic tissue. Prostate 1994;25:199-205.
170. Morris GL, Dodd JG. Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 1990; 143:1272-4.
171. Fiorelli G, DeBellis A, Longo A, Pioli P, Constantini A, Giannini S, et al. Growth factors in the human prostate. J Steroid Biochem Mol Biol 1991;40:199-205.
172. Schuurmans AL, Bolt J, Veldscholte J, Mulder E. Regulation of growth of LNCaP prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 1991;40:193-7.
173. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Hittmair A, Zhang J, et al. Regulation of prostatic growth and function by peptide growth factors. Prostate 1996;28:392-405.
174. Eisemann A, Ahn JA, Graziani G, Ronick SR, Ron D. Alternative splicing generates at least five different isoforms of the human basic-EGF receptor [published erratum appears in Oncogene 1991;6:2379] Oncogene 1991;6:1195-202.
175. Johnson DE, Lu H, Chen H, Werner S, Williams LT. The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain. Mol Cell Biol 1991;11:4627-34.
176. Werner S, Duan DR, De Vies C, Peters KG, Johnson DE, Williams LT. Differential slicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992;12:82-8.
177. Woodward WR, Nishi R, Meshul CK, Williams TE, Coulombe M, Eckenstein FP. Nuclear and cytoplasmic localization of basic fibroblast growth factor in astrocytes and CA2 hippocampal neurons. J Neurosci 1992;12:142-52.
178. Abraham JA, Whang JL, Tumolo A, Mergia A, Freidman J, Gospodarowicz D, Fiddes JC. Human basic fibroblast growth factor: nucleotide sequence and genomic organisation. EMBO J 1986; 5:2523-8.
179. Shibata F, Baird A, Florkiewicz RZ. Functional characterization of the human basic fibroblast growth factor gene promoter. Growth Factors 1991;4:277-87.
180. Baird A, Esch F, Bohlen P, Ling N, Gospodarowicz D. Isolation and partial characterization of an endothelial cell growth factor from the bovine kidney: homology with basic fibroblast growth factor. Regul Pept 1985;12:201-13.
181. Schweigerer L, Nuefeld G, Freidman J. Capillary endothelial cells express basic fibroblast growth factor, a mitogen which promotes their own growth. Nature 1987;325:257-9.
182. Slack JM, Darlington BG, Heath JK, Godsave SF. Mesoderm induction in early Xenopus embryos by heparin-binding growth factors. Nature 1987;326:197-200.
183. Chamberlain, CG, McAvoy JW. Evidence that fibroblast growth factor promotes lens fibre differentiation. Curr Eye Res 1987;6: 1165-8.
184. Schubert D, Ling N, Baird A. Multiple influences of a heparin-binding growth factor on neuronal development. J Cell Biol 1987;104:635-43.
185. Luo D, Lin Y, Liu X, Qin Z, Zhao C, Zhang Y, Yu Z. Effect of prostatic growth factor, basic fibroblast growth factor, epidermal growth factor and steroids on the proliferation of human fetal prostatic fibroblast. Prostate 1996;28:352-8.
186. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK. Influence of transforming growth factor beta 1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 1993;22:183-97.
187. Katz AE, Benson MC, Wise GJ, Olsson CA, Bandyk MG, Sawczuk IS, et al. Gene activation during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 1989;49:5889-94.
188. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voight KD, Knabbe C. Regulation of fibroblast growth factor-like proteins in the androgen-responsive human prostate cell line, LNCaP. J Steroid Biochem Mol Biol 1992;41:659-63.
189. Geller J, Sionit LR, Baird A, Kohls M, Connors KM, Hoffman RM. In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentration in the human prostate. Prostate 1994; 25:206-9.
190. Sato N, Watabe Y, Suzuki H, Shimazaki J. Progression of androgen-sensitive mouse tumor (Shionogi carcinoma 115) to androgen-insensitive tumor after long-term removal of testosterone. Jpn J Cancer Res 1993;84:1300-8.
191. Weidner N, Carroll PR, Flas J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate cancer. Am J Pathol 1993;43:401-9.
192. Brawn PN. The dedifferentiation of prostate carcinoma. Cancer 1983;53:246-51.
193. Sugimura Y, Foster BA, Hom YK, Lipschutz JH, Rubin JS, Finch PW, et al. Keratinocyte growth factor (KGF) can replace testosterone in the ductal branching morphogenesis of the rat ventral prostate. Int J Dev Biol 1996;40:941-51.
194. Story MT, Hopp KA, Molter M, Meier DA. Characteristics of FGF-receptors expressed by stromal and epithelial cells cultured from normal and hyperplastic prostates. Growth Factors 1994; 10:269-80.
195. Peehl DM, Wong ST, Rubin JS. KGF and EGF differentially regulate the phenotype of prostatic epithelial cells. Growth Regul 1996;6:22-31.
196. Pietrzkowski Z, Mulholland G, Gomella IL, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993;53:1102-6.
197. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-like growth factor 1: action and receptor characteristics in human prostatic cancer cell lines. Prostate 1993;22:243-52.
198. Rajah R, Bhala A, Nunn SE, Peehl DM, Cohen P. 7S nerve growth factor is an insulin-like growth factor-binding protein protease. Endocrinology 1996;137:2676-82.
199. Okazaki R, Conover CA, Harris SA, Spelsberg TC, Riggs BL. Normal human osteoblast-like cells consistently express genes for insulin-like growth factors 1 and 11, but transformed osteoblast cell lines do not. J Bone Miner Res 1995;10:788-95.
200. Kaul L, Heshmat M, Kovi J, Jackson MA, Jackson MG, Jones GW, Enterline JP, Worrell RG, Perry SL. The role of diet in prostate cancer. Nutr Cancer 1987;9:123-8.
201. Rogers MB, Rosen V, Wozney JM, Gudas LJ. Bone morphogenic proteins -2 and -4 are involved in the retinoic acid-induced differentiation of embryonal carcinoma cells. Mol Biol Cell 1992; 3:189-96.
202. Glick AB, Flander KC, Danielpour D, Yuspa SH. Retinoic acid induces transforming growth factor beta 2 in cultured keratinocytes and mouse epidermis. Cell Regul 1989;1:87-97.
203. Schofield PN, Ekstrom TJ, Granerus M, Engstrom W. Differentiation associated modulation of K-FGF expression in a human teratocarcinoma cell line and in primary germ cell tumours. FEBS Lett 1991;280:8-10.
204. Reichel H, Norman AW. Systemic effects of vitamin D. Annu Rev Med 1989;40:71-8.
205. Norman AW, Roth J, Orch L. The vitamin D endocrine system. Steroid metabolism, hormone receptors and biological response. Endocr Rev 1982;3:331-66.
206. Feldman D, Skowronski RJ, Peehl DM. Vitamin D, prostate cancer. Adv Exp Med Biol 1995;375:53-63.
207. Pols HAP, Birkenhager JC, Foekens JA, Van Leeuwen JPTM. Vitamin D. A modulator of cell proliferation and differentiation. J Steroid Biochem 1190;37:873-6.
208. Esquenet E, Swinnen JV, Heyns, Verhoeven G. Control of LNCaP proliferation and differentiation: actions and interactions of androgens, 1α,25-dihdroxycholecalciferol, all-trans retinoic acid, 9-cis retinoic acid and phenylacetate. Prostate 1996;28:182-94.
209. Dahiya R, Boyle B, Park HD, Kurhanewicz J, Macdonald JM, Narayan P. 13-cis-Retinoic acid-mediated growth inhibition of DU-145 human prostate cancer cells. Biochem Mol Biol Int 1994;32:1-12.
210. Liu DF, Rabbani SA. Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC-3. Prostate 1995;27:269-76.
211. Young CY, Murtha PE, Andrews PE, Lindzey JK, Tindall DJ. Antagonism of androgen action in prostate tumor cells by retinoic acid. Prostate 1994;25:39-45.
212. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? [Hypothesis]. Anticancer Res 1990;10:1307-12.
213. Braun MM, Helzlsouer KJ, Hollis BW, Comstock GW. Prostate cancer and prediagnostic levels of serum vitamin D metabolites. Cancer Causes Control 1995;6:235-9.
214. Corder EH, Freidman GD, Vogelman JH, Orentreich N. Seasonal variation in vitamin D, vitamin D binding protein and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomark Prev 1995;4:655-9.
215. Skowronski RJ, Peehl DM, Feldman D. Vitamin D, prostate cancer: 1,25-dihydroxy vitamin D3 receptor and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-60.
216. Drivdahl RH, Loop SM, Andress DL, Ostenson RC. IGF-binding proteins in human prostate tumor cells: expression and regulation by 1,25-dihydroxyvitamin. Prostate 1995;26:72-9.
217. Danielpour D, Kadomatsu K, Anzano MA, Smith JM, Sporn MB. Development and characterisation of nontumorigenic and tumorigenic epithelial cell lines from rat dorsal-lateral prostate. Cancer Res 1994;54:3413-21.
218. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996;56:4108-10.
219. Blutt SE, Allegretto EA, Pike JW, Weigel NL. 1,25-Dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology 1997;138:1491-7.
220. Seldmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, et al. Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Ann Surg Oncol 1995;2:550-6.
221. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, et al. A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 1997;39:349-56.
222. De Coster R, Wouters W, Bruynseels J. P450-dependent enzymes as targets for prostate cancer therapy. J Steroid Biochem Mol Biol 1996;56:133-43.
223. 3-E1. J Bone Miner Res 1995;10:222-30.
224. Okazaki R, Durham SK, Riggs BL, Conover CA. Transforming growth factor-beta and forskolin increase all classes of insulin-like growth factor-1 transcripts in normal human osteoblast-like cells. Biochem Biophys Res Commun 1995;207:963-70.
225. Konety BR, Getzenberg RH. Novel therapies for advanced prostate cancer. Semin Urol Oncol 1997;15:33-42.
226. Rago R, Mitchen J, Cheng AL, Oberley T, Wilding G. Disruption of cellular energy balance by suramin in intact prostatic carcinoma cells, a likely antiproliferative mechanism. Cancer Res 1991;51: 6629-35.
227. Rago RP, Brazy PC, Wilding G. Disruption of mitochondrial function by suramin measured by rhodamine 123 retention and oxygen consumption in intact DU145 prostate carcinoma cells. Cancer Res 1992;52:6953-5.
228. La Rocca RV, Danesi R, Cooper MR, Jamis-Dow CA, Ebing MW, Linehan WM, Myers CE. Effect of suramin on human prostate cancer cells in vitro. J Urol 1991;145:393-8.
229. Peehl DM, Wong ST, Stamey TA. Cytostatic effects of suramin on prostate cancer cells cultured from primary tumors. J Urol 1991;145:624-30.
230. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, et al. Suramin: a novel growth factor antagonist with activity in hormone-refactory metastatic prostate cancer. J Clin Oncol 1992;10:875-7.